Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Vanguard Group has become a substantial holder in Neuren Pharmaceuticals Limited, acquiring a 5.023% voting power through various mutual funds and accounts. This acquisition highlights Vanguard’s strategic interest in Neuren, potentially impacting the company’s market dynamics and signaling confidence in its future prospects.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is engaged in creating innovative treatments to address unmet medical needs in this specialized market.
Average Trading Volume: 590
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $983.7M
Learn more about NEU stock on TipRanks’ Stock Analysis page.